• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Members Area |
  • Contact Us
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
    • LSBC Hall of Fame
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Algernon Pharmaceuticals

Member Profile

Algernon Pharmaceuticals is a clinical stage drug development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and stroke. The Algernon drug development program was the brainchild of Dr. Mark Williams, whose innovative approach to drug discovery was developed over many years as senior scientist in the drug development industry. The company and its business model are highly capital efficient and strives to deliver maximum shareholder value. Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life. In addition to drug repurposing Algernon is on the forefront of psychedelic research with their clinical program investigating N,N-Dimethyltryptamine (DMT) as a neuroprotective and neurodegenerative agent in stroke.

Sector
Biotechnology, Global Pharmaceutical Corporations, Therapeutics
Area of Expertise
  • Drug Delivery
  • Drug Discovery
  • Psychedelics
  • Therapeutics
  • Wellness solutions
Company Stage Clinical Stage, Public Company
Stock Ticker AGN - CSE
Stock Ticker AGNPF - OTCQB
Pitch Deck
Additional Document

Member Profile

Biotechnology, Global Pharmaceutical Corporations, Therapeutics

Algernon Pharmaceuticals

Algernon pharmaceuticals black logo
  • Website algernonpharmaceuticals.com/
  • Email info@algernonpharmaceuticals.com
  • Address
    400-601 West Broadway
    Vancouver, BC
    V5Z 4C2
  • Leadership Contact
    Christopher J. Moreau, CEO
    Follow us:
  • Twitter
  • LinkedIn
  • News
  • Jobs

March 21, 2023

Algernon Pharmaceuticals Announces Launch of Rights Offering

March 2, 2023

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

February 21, 2023

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

February 16, 2023

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

January 17, 2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

No current content.

  • Twitter
  • Linkedin
Tweets by Algernon Pharmaceuticals
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us